Provided are thiol-ene polymer networks which can reduce the ROS species that contribute to delayed bone healing and fusion. Furthermore, patients that suffer from neuropathic comorbidities such as diabetes suffer from a diminished healing capacity. An increase in proinflammatory factors and the high presence of reactive oxygen species (ROS) present in diabetics are linked to lower fusion rates. To this end, there is a need for a clinically relevant bone graft to promote bone fusions in patients with neuropathic comorbidities. Incorporating thiol-ene networks for bone scaffolds has demonstrated increased osteogenic biomarkers over traditional polymeric materials and act as antioxidants. Thiol-ene networks offer improved bone grafts for diabetic patients by reducing the number of hydroxyl radicals associated with neuropathic comorbidities. These networks are particularly well suited in promoting healing in patients with Type II Diabetes or other conditions exacerbated by ROS-mediated damage.

A method for monitoring a treatment of a subject having a musculoskeletal disorder is provided. The method includes measuring a first expression level of at least two biomarkers at a treatment site prior to the treatment and measuring a second expression level of the at least two biomarkers at the treatment site after the treatment begins. The method further includes comparing the first expression level of the at least two biomarkers prior to the treatment to the second expression level of the at least two biomarkers post treatment and continuing the treatment, altering the treatment or stopping the treatment based on the comparison. A method of treating a musculoskeletal disorder in a subject is also provided. The method includes removing a aggrecan-hyaluronan matrix from a treatment site in the subject.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced ability, to assemble a functional dystrophin-associated glycoprotein complex (DGC) that results in an inability, or reduced ability, to establish cell polarity. The method includes administering to the patient a sufficient amount of an epidermal growth factor receptor (EGFR) pathway activator to stimulate asymmetric division of at least some satellite stem cells.

The present invention discloses a compound of general formula I, or a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof, a composition comprising the compound of general formula I, and use of the compound of general formula I, or the pharmaceutically acceptable salt, the stereoisomer, the ester, the prodrug, the solvate and the deuterated compound thereof for preparing a medicament for treating a disease associated with the serine/threonine kinase family (MAP4Ks), and preferably for preparing a medicament for treating a disease associated with hematopoietic progenitor kinase 1 (HPK1).

##STR00001##

A drug delivery system is described comprising a detachable support and a plurality of drug-loaded transdermal microneedles, for delivering drugs into gingival tissue for the treatment of periodontal disease.

The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

The present disclosure provides compositions and methods for managing female infertility, caused by reduced thickness and receptivity of the endometrial lining. More particularly, the present disclosure provides a platelet derived growth factor concentrate and a composition comprising the same, preferably in combination with a stimulus responsive polymer. Consequently, methods to obtain the said compositions, along with therapeutic applications in improvement in thickness and receptivity of the endometrial lining are provided.

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.